WASHINGTON, DC, March 2, 2016 – The Alliance for Regenerative Medicine (ARM) today announced its sixth annual Advanced Therapies Summit will take place April 6, 2016 in Stockholm, Sweden. This one-day meeting is a gathering of the sector’s top executives, clinical researchers and policymakers across Europe and the United States to discuss how best to support the Advanced Therapies Medicinal Products (ATMP) sector.
This multi-stakeholder, interactive forum will feature high-level roundtable discussions and ample networking opportunities with leading international advanced therapies companies utilizing gene therapy, cell therapy and other regenerative medicine technologies.
ARM Managing Director Morrie Ruffin and PharmaCell CEO Alexander Vos will kick off the event with a detailed overview of the current state of the sector, including the partnering and dealmaking environment; financial trends; recent accomplishments; anticipated clinical data milestones; and current regulatory priorities.
Experts and key opinion leaders will lead interactive conversations around important and timely issues affecting the sector today, including the industrialization of cell therapy products; ATMP development and regulatory challenges; pharma’s investment in gene and cell therapy; adaptive pathways, early market access and reimbursement for ATMP products; and more.
“Exchanging views and building a stronger international network is key to the continued growth and development of the ATMP sector in Europe and around the world,” said Morrie Ruffin, ARM managing director. “This event provides the opportunity for substantial interaction and discussion among the most influential companies and organizations currently active in our community.”
Top industry CEOs, senior executives, translational experts and policymakers will lead the Summit’s roundtable discussions, representing companies, organizations and agencies from across the sector, including bluebird bio; Cell and Gene Therapy Catapult; European Medicines Agency (EMA); GE Healthcare Life Sciences; GlaxoSmithKline; Janssen Research & Development; National Institute for Health and Care Excellence (NICE); Pluristem Therapeutics; Sangamo BioSciences; and more.
A finalized agenda and speaker list will be announced in the coming weeks.
Registration is now open – to learn more and to secure a spot, please visit ARM’s event page. For media interested in attending, please contact Lyndsey Scull (firstname.lastname@example.org) for information regarding complimentary press registration.
The event will be held at the Scandic Victoria Tower; Arne Beurlings Torg 3; 164 40 Kista in Stockholm, Sweden.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 240 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.